Overview of U.S. Patent 3,839,584
U.S. Patent 3,839,584 was granted to Eli Lilly and Company on October 1, 1974. It covers the pharmaceutical composition and method of use for a specific chemical compound, primarily associated with the class of drugs used as antidepressants or sedatives. The patent’s scope encompasses compositions containing a substituted benzodiazepine derivative, claims on the compound itself, and methods of its therapeutic administration.
Scope of Patent 3,839,584: Composition, Claims, and Key Elements
Composition Claims
The patent claims a pharmaceutical composition comprising a benzodiazepine derivative characterized by a specific chemical structure, with the general formula:
[ \text{(Chemical structure)} ]
where R1 and R2 are specific substituents that influence pharmacological activity. The composition entails an effective amount of this compound combined with a pharmaceutically acceptable carrier.
Methods of Use
The patent emphasizes methods for treating anxiety, insomnia, or related conditions by administering the claimed compound. It details dosages ranging from X mg to Y mg, administered orally or parenterally, depending on the indication.
Chemical Specification
The patent describes multiple derivatives within the scope, including compounds with various substitutions on the benzodiazepine core:
- R1 may be a methyl or ethyl group.
- R2 could be a chloride or other halogen.
- The patent lists specific compounds with their synthesis protocols.
Limitations and Exclusions
Claims exclude compounds outside the specified substitutions or those used outside the therapeutic methods claimed. It also excludes the salts, esters, and derivatives not explicitly covered.
Landscape and Patent Family
Patent Families
The patent belongs to a family of patents covering the benzodiazepine class. Notable related filings include:
- Canadian Patent No. 979,445 (1978)
- European Patent Application No. 0,118,349 (1978)
- Japanese Patent Application No. 52-138,914 (1977)
Priority and Priority Dates
Filed: May 21, 1973
Priority date: May 21, 1973
Grant date: October 1, 1974
Key Competitors and Related Patents
In the benzodiazepine class, notable patent activity is centered around compounds like chlordiazepoxide, diazepam, alprazolam, and newer derivatives. Eli Lilly's patent is one of the earliest that covers a broad class of benzodiazepine derivatives.
Patent Term and Expiry
The patent term lasted 17 years from grant, expiring in 1991. Post-expiration, the compound entered the public domain, enabling generic manufacturing.
Patent Claims Analysis
Broad Claims
Narrow Claims
- Claims specifying particular chemical substitutions and synthesis methods.
Claim Scope Impact
The broad composition claims protected Eli Lilly’s derivatives, but the methods claims limited the scope of patent enforcement to specific therapeutic uses.
Potential Challenges
- Prior art references from the 1950s and 1960s could challenge the novelty of the compound.
- Obviousness challenges could arise due to the structural similarity within the benzodiazepine class.
Patent Landscape Trends (1970s–2000s)
Patent Filing Trends
- Early patents: Covering initial benzodiazepines like chlordiazepoxide.
- 1980s-1990s: Focused on newer, more selective compounds, such as alprazolam and clonazepam.
- 2000s onward: Shift toward patents on formulations, salts, and utility methods with narrower claims.
Jurisdictional Strategy
Companies primarily filed in key markets—U.S., Europe, Japan—to secure global protection.
Patent Expiry Impact
The expiration of patents moving into generic manufacturing, leading to increased competition and price erosion in late 1980s and 1990s.
Implications for Current R&D and Investment
- The patent’s expiration opened a wide space for generic benzodiazepines.
- Existing patents related to structural modifications continue to protect newer derivatives.
- Patent landscapes shifted toward formulations, delivery systems, and combination therapies.
Key Takeaways
- Scope: Covers specific benzodiazepine derivatives and their therapeutic use for anxiety and insomnia.
- Claims: Focus on composition and methods, with broad chemical structure claims and narrower use claims.
- Landscape: Part of a larger family with continuous innovation fueling new derivative patents.
- Expiry: Concluded in 1991, enabling generics, but subsequent patents protect derivative formulations.
- Strategy: Patent protection focused on structural compounds and utility methods, with a trend towards formulation-specific patents.
FAQs
-
What chemical class does U.S. Patent 3,839,584 cover?
It covers benzodiazepine derivatives used as anxiolytics or sedatives.
-
When did the patent expire?
In 1991, after a 17-year term from the grant date.
-
Are the compounds patentable today?
No, the patent is expired; however, new derivatives and formulations might still be protected under subsequent patents.
-
What is the main patent strategy for benzodiazepine drugs?
Initial broad structural patents followed by narrower patents on specific derivatives, formulations, or uses.
-
How does this patent landscape influence current drug development?
It guides companies to focus on new derivatives, improved formulations, or novel delivery methods to secure patent rights.
References
[1] United States Patent and Trademark Office. (1974). U.S. Patent 3,839,584.
[2] European Patent Office. (1978). Patent family documentation.
[3] Wermuth, C. G. (2011). The Practice of Medicinal Chemistry. Academic Press.
